Insider share sale at current price, lack of insider buying, and insignificant insider ownership suggest caution before buying the stock, despite company's profitability and profit growth.
The company's consistent but low ROCE and the increase in capital employed without a corresponding increase in returns may be factors contributing to its relatively modest stock gain. The analysis suggests looking at other options for potential multi-baggers.
MMSI's shares are trading above fair value due to its positive outlook. Despite overvaluation, the company's expected higher cash flow could lead to a higher share valuation.
Merit Medical Systems' strong EPS growth is attractive to investors, as is the fact that insiders hold a substantial stake in the company. Because of this, further investigation into the company's true value is recommended.
The business isn't making high-return investments despite an increase in its capital employed. Even though Merit Medical Systems is increasing its capital, diminishing returns on said capital make it less attractive as a high-value growth stock.
The market sentiment looks positive as Merit Medical Systems turned profitable in the recent years. The company shows signs of improvement over time, with its gains better than the average annual return over the past five years.
The underpriced stock of Merit Medical Systems is a lucrative opportunity for investors, although a careful consideration of the company's financial health is advised. The future outlook for the company looks optimistic, yet this isn't entirely mirrored in its current share price. Don't forget to assess the company's balance sheet strength before investing.
The sales of shares by multiple insiders, including the founder, at prices close to the current stock price raises some concern. However, the 2.3% of the company owned by insiders indicates some level of alignment between management and smaller shareholders.
$Merit Medical Systems(MMSI.US)$5年來營收除2020年下滑3.1%以外增長了4年,平均增速爲9.6%,營業利潤則在2019年大幅下滑33.3%,之後連續增長3年,5年平均增速爲17%,近兩年平均增速48%,淨利潤則在2020年陷入虧損,近兩年大幅增長至0.745億。2020年虧損主要是資本性資產減值和其他特殊費用造成的,其餘幾年這個科目也一直不乾淨。 2023Q1營收增長8%,營業利潤增長38%,淨利潤增長96%,淨利潤增速大幅高於毛利潤主要是其他費用轉變爲其他收益的結果。 目前市盈率64,市盈率TTM降到了56,雖然相對於利潤增速來說不高,但是高增速通常很難持久,可以多等待幾個季度再說。
Merit Medical Systems股票討論區
2023Q1營收增長8%,營業利潤增長38%,淨利潤增長96%,淨利潤增速大幅高於毛利潤主要是其他費用轉變爲其他收益的結果。
目前市盈率64,市盈率TTM降到了56,雖然相對於利潤增速來說不高,但是高增速通常很難持久,可以多等待幾個季度再說。
專欄Today's pre-market stock movers: F, META, BBY, QCOM and more
In reaction to earnings/guidance:
$Sunnova Energy International(NOVA.US)$ +13.6%,$Impinj(PI.US)$ +12%,$Etsy Inc(ETSY.US)$ +8.1%,$argenx SE(ARGX.US)$ +8.1%,$Netgear(NTGR.US)$ +6.9%,$福特汽車(F.US)$ +6.7%(also increases dividend),$Myovant Sciences(MYOV.US)$ +6%,$Merit Medical Systems(MMSI.US)$ +6%,$伊格爾礦業(AEM.US)$ +5.8%,$偉創力(FLEX.US)$ +5.1%,$MAA房產信托(MAA.US)$ +5%,$普雷克薩斯(PLXS.US)$ +5%,$哈雷戴維森(HOG.US)$ +5%,...
暫無評論